CRBN-based selective IKZF1/3 degrader

oral efficacy in lenalidomide-resist. xenograft

from phenotypic screen and optimization

J. Med. Chem., Mar. 4, 2020

Celgene, San Diego, CA

Structure of compound CC-92480

CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: